The New England Journal of Medicine

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited ...
Medscape

Inhibition of the Renin Angiotensin Aldosterone System in Black Populations -- Does It or Doesn't It Work?

Unique Characteristics of Hypertension in Blacks That Influence BP Responses to Drugs That Block the Renin-Angiotensin Activating System (RAAS) Blockade of the RAAS in Blacks for Cardiovascular and ...
News Medical

Umbrella analysis of the effect of renin-angiotensin-aldosterone system inhibitors on COVID-19 related outcomes

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...
Renal & Urology News

RAAS Inhibitor Discontinuation After Hyperkalemia Tied to Adverse Outcomes

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...
The New England Journal of Medicine

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), ...